HOME >> BIOLOGY >> NEWS
Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

The number of lymph nodes that contain evidence of cancer is the best predictor of the effectiveness of adding chemotherapy and radiation to a treatment plan prior to surgery in individuals with oesophageal cancer, according to a study published last month in the Annals of Surgery. The authors say their finding is particularly important because the focus of recent pathological studies of response to neoadjuvant therapies has been on the primary tumour rather than nodal sites.

Multimodal neoadjuvant therapy---where suitable patients are given several cycles of drugs and radiation therapy before undergoing surgical procedures to remove their tumour---is increasingly being used by oncologists as a way to boost survival rates from oesophageal cancer which, even with the most radical surgery, remain low: only 50% of patients survive for 3 years. However, the evidence for which additional therapies work best is confusing and conflicting. What is more, although it is widely accepted that there is a group of patients in whom this approach works well, identifying who these patients are is no easy task.

To help find ways of pinpointing individuals who might respond best to neoadjuvant treatment, John Vincent Reynolds and colleagues followed the progress of 243 patients who were treated with chemotherapy and radiation before surgery over 5 years. They paid particular attention to the histomorphological responses of patients---changes in the structure and appearance of tissue samples when viewed under a microscope---in addition to assessing prognosis using the traditional TNM method of staging, which takes into account tumour size, involvement of lymph nodes (nodal status), and presence or absence of metastases.

The study group consisted of all patients undergoing neoadjuvant treatment for oesophageal cancer at St James Hospital in Dublin,Ireland. Patients with oesophageal cancer were deemed suitable for multimodal therapy if they fulfilled
'"/>

Contact: Corinne Hall
mediaservice@esoncology.org
39-028-546-4522
European School of Oncology
13-Jul-2007


Page: 1 2 3

Related biology news :

1. MU researchers to study the status of black bears in Missouri
2. Green sturgeon receives threatened status
3. High-status monkeys ignore the interests of riff-raff
4. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible status
5. Sudden change in social status triggers genetic response in male fish, study finds
6. Manatee eyes could be window to health status
7. Location, location, location: Effect of nuclear organization on transcriptional status
8. Biologists findings on fertility and status in monkeys generate scientific, media interest
9. MIDI, Inc receives Official Methods(SM) status for the confirmatory ID of the anthrax pathogen
10. Study in Royal Society journal on how relationship status influences sex ratios
11. DNA highly promising predictor for successful treatment of alcoholics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Vehicle Access System Market Analysis & Trends - Industry Forecast to ... ... poised to grow at a CAGR of around 15.1% over the ... This industry report analyzes the market estimates and forecasts for ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... -- The National Pharmaceutical Council (NPC) today announced that Ipsen ... as its newest member. David Cox , PhD, ... America ), will serve as his company,s representative ... to have Ipsen and Dr. Cox join NPC as ... welcome their insights in helping us identify and address ...
(Date:3/28/2017)... March 28, 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... of novel therapies for metabolic and endocrine disorders, today ... , Ph.D., will deliver a corporate presentation at H.C. ... Conference, being held April 3, 2017 at the St. ... for this presentation are as follows: ...
(Date:3/28/2017)... 28, 2017 Dr. Chris Yu ... corporation Anpac Bio-Medical Science Company , announced ... record, processing and reporting over 40,000 cases worldwide ... (CDA) liquid biopsy tests. Described ... Summit publications, Anpac Bio,s CDA medical devices and ...
(Date:3/28/2017)... , March 28, 2017 Biostage, Inc. ... company developing bioengineered organ implants to treat cancers and ... today announced that Jim McGorry, CEO of ... BioEngineering panel at the MassBio 2017 Annual ... PM ET in Cambrige, Massachussetts. The 3D Printing ...
Breaking Biology Technology:
Cached News: